82
Pharma & HealthcareStrong Buy
SBI Healthcare Opportunities
SBI · Direct–Growth · rank #1 of 19 by Smart Score
Data updated
Trailing returns
1 Year
26.1%
+25.4% vs index
3 Years
24.6%
+13.1% vs index
5 Years
20.7%
+10.6% vs index
Since launch
18.4%
Year-by-year performance
2021
+21.5%-9.1% vs index
2022
-5.0%-8.8% vs index
2023
+39.7%+13.2% vs index
2024
+43.8%+28.1% vs index
2025
-2.5%-10.2% vs index
2026
+29.1%+28.2% vs index
Why this score
SBI Healthcare Opportunities scores 82/100 — the top-rated Pharma & Healthcare fund of 19 (Strong Buy). It stands out for 5y return and 3y return — beating 95% of peers on 5y return. It has no major weak spot vs the category.
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
5Y return20.68% · 95th percentile in category
3Y return24.60% · 88th percentile in category
Sharpe ratio1.23 · 91st percentile in category
Sortino ratio1.95 · 90th percentile in category
Fund size6062.71 Cr · 87th percentile in category
Volatility14.43 · 66th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd10.55%
2.Divi's Laboratories Ltd8.38%
3.Max Healthcare Institute Ltd4.96%
4.Ami Organics Ltd4.95%
5.Apollo Hospitals Enterprise Ltd4.87%
37 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.